Clinical trial • Not applicable • Musculoskeletal

OXYGEN for Acute hamstring injury

Not applicable trial of OXYGEN for Acute hamstring injury. open-label, historical control group (standard care).. 50 participants.

Overview

Trial Therapeutic Area
Musculoskeletal
Trial Disease
Acute hamstring injury
Trial Stage
Not applicable
Drug Modality
Other

Key dates

Initial CTIS Submission Date
18-12-2023
First CTIS Authorization Date
22-04-2024

Trial design

open-label, historical control group (standard care). Not applicable trial in Netherlands.

Open Label
Yes
Comparator
Historical control group (standard care).
Real World Control
Yes
Target Sample Size
50

Eligibility

Recruits 50 No vulnerable population selected. Participants must provide signed informed consent. Eligible ages 18-65. No assent procedures or special consent provisions for minors described..

Pregnancy Exclusion
pregnancy or claustrophobia
Vulnerable Population
No vulnerable population selected. Participants must provide signed informed consent. Eligible ages 18-65. No assent procedures or special consent provisions for minors described.

Inclusion criteria

  • {"criterion_text":"- The participant is 18-65 years old\n- The participant has a clinical diagnosis of an acute hamstring injury ≤7 days old, defined as: a) Anamnestic acute injury; b) Anamnestic pain in the posterior thigh; c) Localized pain during plapation of the hamstring muscle; d) Localized pain during passive straight leg raise test e) Increased pain during isometric contraction\n- The participant is able to start HBOT ≤7 days of injury\n- Signed informed consent"}

Exclusion criteria

  • {"criterion_text":"- There are contra-indications for hyperbaric oxygen therapy: Smoking or quit smoking <3 months prior to injury, a previous spontaneous pneumothorax, a ICD or pacemaker not compatible with hyperbaric pressure, Current or recent (6 months) use of cytostatics, Unable to perform a Vasalva manoeuvre to pressurize the middle ear, pregnancy or claustrophobia\n- The participant does not have the intention to return to full sporting / -duty activities.\n- The cause of the hamstring injury is an extrisic trauma on the posterior thigh\n- The participant has a chronic injury (>2 months), defined as reccurent pain or tenderness of the hamstring muscles.\n- The current injury is a hamstring re-injury, defined as: A repeat injury <2 months following Return to play / return to full unrestricted duty from a previous hamstring injury;\n- The current injury is a complete proximal tendon avulsion (grade III hamstring injury)\n- There are other, concurrent injuries inhibiting rehabilitation\n- There are contra-indications for MRI: Incompatible pacemakers/ICD's, pregnancy or claustrophobia."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Time needed to return to play (days) for athletes or time needed to return to full unrestricted duty (days) for military personnel.","definition_or_measurement_approach":"Measured as time in days to return to play (RTP) for athletes or time in days to return to full unrestricted duty for military personnel."}

Secondary endpoints

  • {"endpoint_text":"- Patient reported hamstring scores: Tenger activity score, Functional assessment scale for acute hamstring injuries and psychological readiness.\n- Maximum and mean pain scores (0-10) assessed with the visual analog scale, at injury, at rest and during sprinting\n- Physical examination including: - Palpation: Location and dimension of painful area/lesion, presence of hematoma or – swelling o Pain with isometric contraction - Hamstring flexibility tests: Passive straight leg raise, Active knee extension test. - Hamstring isometric strength (Hand hold dynamometer)\n- MRI derived parameters: Aspect of the injury on T1 and T2- weighted images scored by a radiologist using a standardized form.\n- Number of re-injury at 2- and 12 months following return to play/ return to full unrestricted duty.\n- Number of (serious)adverse events from inclusion to ≤7 days following the last hyperbaric oxygen treatment session.","definition_or_measurement_approach":"Patient-reported outcomes: validated scores (Tenger activity score, Functional assessment scale, psychological readiness). Pain: VAS 0-10 at injury, rest and during sprinting. Physical exam: palpation, pain with isometric contraction, PSLR and AKE flexibility tests, isometric strength measured with handheld dynamometer. MRI: radiologist scoring of T1/T2 images using standardized form. Re-injury: count of re-injuries at 2 and 12 months following RTP. Safety: count of (serious) adverse events from inclusion to ≤7 days after last HBOT."}

Recruitment

Planned Sample Size
50
Recruitment Window Months
72
Consent Approach
Signed informed consent is required from participants. Eligible participants are adults 18-65. No assent procedures for minors described. Study documents include Dutch translations of key text; specific consent document languages not detailed.

Geography

Total Number Of Sites
1
Total Number Of Participants
50

Netherlands

Earliest CTIS Part Ii Submission Date
08-04-2024
Latest Decision Or Authorization Date
22-04-2024
Processing Time Days
14
Number Of Sites
1
Number Of Participants
50

Sites

Site Name
Amsterdam UMC
Department Name
Orthopedic Surgery & Sports medicine
Principal Investigator Name
J.L. Tol
Principal Investigator Email
ctis@amsterdamumc.nl
Contact Person Name
J.L. Tol
Contact Person Email
ctis@amsterdamumc.nl

Sponsor

Primary sponsor

Full Name
Amsterdam UMC
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Third parties

  • {"country":"","full_name":"ZonMW","duties_or_roles":"Monetary support","organisation_type":""}
  • {"country":"","full_name":"NOC-NSF","duties_or_roles":"Monetary support","organisation_type":""}

Investigational products

Investigational Product Name
Conoxia, 100% v/v, medicinaal gas, samengeperst
Active Substance
OXYGEN
Modality
Other
Routes Of Administration
INHALATION
Route
INHALATION
Authorisation Status
Authorised (marketing authorisation RVG 30355)
Maximum Dose
maxTotalDoseAmount 12100 l
Investigational Product Name
Conoxia® Vloeibaar, 100% v/v, medicinaal gas, cryogeen
Active Substance
OXYGEN
Modality
Other
Routes Of Administration
INHALATION
Route
INHALATION
Authorisation Status
Authorised (marketing authorisation RVG 100211)
Maximum Dose
maxTotalDoseAmount 12100 l

Related trials

Other published trials that may interest you.